Manufacturing Facilities 1,50,000 sq. ft. covered area 5 Dedicated Blocks operating as per US FDA guidelines. 132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters) 3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month. cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters) Fully Automated Solvent Recovery System Biological Waste Water Treatment Plant.
Apart from its existing plants in tax exempted zone of J&K and Baddi, duly certified and approved by WHO GMP, your company has successfully commissioned another Manufacturing facility at the same tax exempted zone and green plains of Baddi during the year. This new manufacturing facility inaugurated in August 2007, is for soft Gelatin Encapsulation with an annual capacity of 36 Crore and will not only make us almost self sufficient in soft gelatin manufacturing but will unquestionably dedicated a bit of spare capacities for contract manufacturing as well.
Company's manufacturing unit at Parwanoo has also been upgrades as per WHO Standards.
Company's Global Business Unit (GBU) at Derabassi has got MHRA & TGA approval.
These new facilities will augment the company's efforts to tap the regulated markets and strengthen the company's growing CRAMS business which is expected to accounts for 30-40% of its bottom line over the next four years. Your company has been certified for ISO 9000:2001 also during the year.
Ind-Swift had recognized the pivotal role that will be played by the R&D much ahead of time and therefore, in spite of several hurdles faced by the Company earlier, it continued to invest in R&D. Today Company's modern R&D set up is the result of that wisdom. Company is well placed to face the post 2005 scenario which still confounds many domestic companies.
In the patent free environment, where there are a plethora of bulk drug manufacturers, the Company has decided to concentrate on those molecules, manufacture of which requires complex chemistry and several reactions steps. This way a lot of fringe players are eliminated and the market is less crowded. A strong R&D set up is inevitable to achieve this.
As a result, we have built up considerable R&D strengths, centered on a knowledge base pool of over 80 scientists and technical personnel are working towards the common goal of achieving excellence in all spheres of activities, be it development of new molecule, changes in the process resulting in cost reduction or improvement in the quality of products. As a result of its R&D initiatives, the Company has been able to introduce several new molecules first time in India. ISLL is a technology driven company. The technologies are not only cost effective, but also give quality products, consistently with higher purity. ISLL has been investing aggressively in its R&D activities, to the level of almost 6% of its turnover.
Our major strengths and core competencies lay in the development and commercialization of Active Pharmaceutical Ingredients (API) in line with regulatory and quality requirements.
Process optimisation and improvement.
Research for APIs/ advance intermediates and fine chemicals
Development of non-infringing processes for promising molecules
Pilot studies of new molecules for clients.
R&D will play a more significant role in future. While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non-infringing routes for the drugs whose patent will expire in coming years.
To enter the regulated markets like USA, EU, Australia, and New Zealand, the Company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.
A new R&D Center with investment of US$ 5 Million is already planned in Mohali with a focus to develop NCEs.
Creative spirit, dedicated effort and application of new technology, form the basis for innovation, which the pharmaceutical industry requ
Research and Development
Our R&D centre is recognised by the Government of India's Ministry of Science & Technology
Taste masking (Coated granulation) technology in macrolides, especially in Clarithromycin, Azithromycin and Roxithromycin
A grant of US patent for Development of non infringing process for Clarithromycin dispersible tablets and Clarithromycin- Once a day, a controlled release formulation completely developed in-house at its R&D centre
Development of different Nitazoxanide dosage forms
Development of Fexofenadine (latest antiallergic) dispersible tablets and ready to file patent for the same
Sustained release form of Isoxsuprine HCl
Mouth dissolving tablet of Betamethasone
Development of tablet in tablet technology
3 patents for API s for non infringing processes filed
All the manufacturing units are designed to comply with current GMP norms as proposed by stringest world regulatory bodies like USFDA, MHRA, EU, and WHO, and accreditations from ISO 14000
Ind-Swift is known as one of the biggest global bulk producers of APIs like clarithromycin, fexofenadine, atorvastatin etc. (For details visit our group company’s website Ind-Swift Labs Limited.)
Launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia
Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trial.
Its pioneering R & D efforts have led to the creation and introduction of blockbuster drugs like:
Atrovastatin – One of the most effective cholesterol lowering drugs with an estimated market size of US$ 12 billion.
Nitazoxanide – a wonder, one of its kind anti-diarroheal with a market of US$ 6 billion.
Pioglitazone – an anti-diabetic drug ranked among the first five in its Therapeutic segment.
Arthrill – an herbal wonder for the treatment of Arthritis.
Anaproct – an ayurvedic product providing relief from piles within 24 hours with no allopathic cometitor.
Aim / Vision / Mission
Wining Global customers through Innovative quality pharmaceuticals products
Quality Policy / Processes
Equipped with state of art quality testing equipment and well trained personnel, Ind-Swift maintains strict quality control, storage to delivery in accordance with GMP and ISO 9002. Quality of product meet the respective requirement of USP/BP/EP/JP etc., as per the international quality standards.
We are leading supplier, exporter and trader of pharmaceutical tablets, generic drugs, combivir tablet, efavir tablet, anti cancer drug and asthmatic inhaler. We also offer arteether injection, antibiotic injection and ceftriaxone & sulbactam injection.
Manufacturer & exporter of ingredients, 1-3 difluorobenzene, 4-methoxybenzoic acid, para amino benzoic acid, para nitro benzoic acids, chondroitin sulphate, difenoconazole, iso propyl myristate 110-27-0, methylene blue and domperidone maleate.